Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21516

Shown on this page

Current sort

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Pregnant Women, Psychotropic Drugs
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma
Interventions: Optune® device, Temozolomide, Pembrolizumab, Placebo; Device · Drug
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Orange, California • Sacramento, California • Stanford, California + 16 more

Conditions: Myelofibrosis, Anemia
Interventions: Placebo, Elritercept; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 35
States / cities: Gilbert, Arizona • Glendale, California • Whittier, California + 27 more

Conditions: Parkinson's Disease
Interventions: BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo; Drug
Lead sponsor: Bial R&D Investments, S.A.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more

Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more

Conditions: Binge-Eating Disorder
Interventions: Solriamfetol, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Encino, California • Long Beach, California • Santa Ana, California + 29 more

Conditions: Abdominal Aortic Aneurysms (AAA)
Interventions: Fenestrated TREO Stent Graft System; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Tampa, Florida • Boston, Massachusetts + 4 more

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: treprostinil SMI (treprostinil inhalation spray), Placebo (placebo inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more

Conditions: Ankle Fractures, Syndesmotic Injury
Interventions: RemeOs Magnesium-Based Biodegradable Screw; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pediatric Brain Tumor
Interventions: HIIT Exercise Program, Control Group; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
Interventions: HistoSonics Edison System; Device
Lead sponsor: HistoSonics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 35
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 28 more

Clinical trials in Boston, Massachusetts

Filter and sort this location

Institutions in Boston

Live official records

National Pregnancy Registry for Psychiatric Medications

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA

Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

Biodegradable Magnesium Screws for Unstable Ankle Fracture Surgery

High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)